Lumito presents at the BioStock Life Science Summit
BioStock Mattias Lundin_Lumito
Kurs
-14,47%
Likviditet
2,60 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-30 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | N/A | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2025-05-07 | N/A | Årsstämma |
| 2025-05-07 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-20 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-08 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-10-31 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-03 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-02 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2022-05-27 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Extra Bolagsstämma 2021 |
| 2021-10-20 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-03 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-17 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-04 | - | Årsstämma |
| 2019-05-23 | - | X-dag ordinarie utdelning LUMITO 0.00 SEK |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
On October 25 at 1 p.m., Mattias Lundin, Lumito's CEO, presents the company at the BioStock Life Science Summit 2023 and answers questions from the moderator.
Where: Medicon Village, Lund
When: October 25 at 1 p.m.
Registration: https://www.biostock.se/en/biostocklifesciencesummit/
The presentation will be held in English.
Tickets to the event are free of charge. The presentation will not be broadcast live but will be available to watch afterwards.
For further information, please contact:
Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09
Lumito
Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Image Attachments
BioStock Mattias Lundin_Lumito